Trial Profile
A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 03 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 09 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Jun 2020.
- 07 Nov 2019 Planned End Date changed from 1 Apr 2021 to 1 Jan 2020.